Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients.
Yoshiya HorimotoYumiko IshizukaYuko UekiToru HiguchiAtsushi ArakawaMitsue SaitoPublished in: BMC cancer (2022)
The prognosis of patients with IHC(2+)/FISH(+) tumors did not differ from IHC(3+) tumors. However, the significance of HER2 protein overexpression in relation to treatment response remains unclear and warrants further investigations.